Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Sex Med ; 10(10): 2586-9, 2013 Oct.
Article in English | MEDLINE | ID: mdl-22594312

ABSTRACT

INTRODUCTION: 17ß-hydroxysteroid dehydrogenase type 3 (HSD17B3) isoenzyme is present almost exclusively in the testes and converts delta 4 androstenedione to testosterone. Mutations in the HSD17B3 gene cause HSD17B3 deficiency and result in 46,XY Disorders of Sex Development (46,XY DSD). AIM: This study aimed to present the clinical and biochemical features of a Tunisian patient who presented a sexual ambiguity orienting to HSD17B3 deficiency and to search for a mutation in the HSD17B3 gene by DNA sequencing. METHODS: Polymerase chain reaction (PCR) amplification and subsequent sequencing of all the coding exons of HSD17B3 gene were performed on genomic DNA from the patient, her family, and 50 controls. RESULTS: Genetic mutation analysis of the HSD17B3 gene revealed the presence of a novel homozygous nonsense mutation in the exon 9 (c.618 C>A) leading to the substitution p.C206X. The mutation p.C206X in the coding exons supports the hypothesis of HSD17B3 deficiency in our patient. CONCLUSION: The patient described in this study represented a new case of a rare form of 46,XY DSD, associated to a novel gene mutation of HSD17B3 gene. The screening of this mutation is useful for confirming the diagnosis of HSD17B3 deficiency and for prenatal diagnosis.


Subject(s)
17-Hydroxysteroid Dehydrogenases/deficiency , Codon, Nonsense , Disorder of Sex Development, 46,XY/genetics , Gynecomastia/genetics , Steroid Metabolism, Inborn Errors/genetics , 17-Hydroxysteroid Dehydrogenases/blood , 17-Hydroxysteroid Dehydrogenases/genetics , Androstenedione/blood , Biomarkers/blood , Child, Preschool , DNA Mutational Analysis/methods , Disorder of Sex Development, 46,XY/blood , Disorder of Sex Development, 46,XY/diagnosis , Disorder of Sex Development, 46,XY/enzymology , Exons , Female , Genetic Predisposition to Disease , Gynecomastia/blood , Gynecomastia/diagnosis , Gynecomastia/enzymology , Homozygote , Humans , Male , Pedigree , Phenotype , Polymerase Chain Reaction , Steroid Metabolism, Inborn Errors/blood , Steroid Metabolism, Inborn Errors/diagnosis , Steroid Metabolism, Inborn Errors/enzymology , Testosterone/blood , Tunisia
2.
Biochim Biophys Acta ; 1822(9): 1397-410, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22465940

ABSTRACT

The importance of peroxisomes in lipid metabolism is now well established and peroxisomes contain approximately 60 enzymes involved in these lipid metabolic pathways. Several acyl-CoA thioesterase enzymes (ACOTs) have been identified in peroxisomes that catalyze the hydrolysis of acyl-CoAs (short-, medium-, long- and very long-chain), bile acid-CoAs, and methyl branched-CoAs, to the free fatty acid and coenzyme A. A number of acyltransferase enzymes, which are structurally and functionally related to ACOTs, have also been identified in peroxisomes, which conjugate (or amidate) bile acid-CoAs and acyl-CoAs to amino acids, resulting in the production of amidated bile acids and fatty acids. The function of ACOTs is to act as auxiliary enzymes in the α- and ß-oxidation of various lipids in peroxisomes. Human peroxisomes contain at least two ACOTs (ACOT4 and ACOT8) whereas mouse peroxisomes contain six ACOTs (ACOT3, 4, 5, 6, 8 and 12). Similarly, human peroxisomes contain one bile acid-CoA:amino acid N-acyltransferase (BAAT), whereas mouse peroxisomes contain three acyltransferases (BAAT and acyl-CoA:amino acid N-acyltransferases 1 and 2: ACNAT1 and ACNAT2). This review will focus on the human and mouse peroxisomal ACOT and acyltransferase enzymes identified to date and discuss their cellular localizations, emerging structural information and functions as auxiliary enzymes in peroxisomal metabolic pathways.


Subject(s)
Acyltransferases/physiology , Lipid Metabolism , Palmitoyl-CoA Hydrolase/physiology , Peroxisomes/enzymology , Acyl Coenzyme A/metabolism , Acyltransferases/genetics , Acyltransferases/metabolism , Animals , Bile Acids and Salts/metabolism , Cholic Acids/blood , Cholic Acids/genetics , Humans , Hydrolysis , Models, Molecular , Palmitoyl-CoA Hydrolase/chemistry , Palmitoyl-CoA Hydrolase/metabolism , Peroxisomes/metabolism , Protein Conformation , Steroid Metabolism, Inborn Errors/enzymology , Steroid Metabolism, Inborn Errors/genetics
3.
J Pediatr Gastroenterol Nutr ; 50(1): 61-6, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19915491

ABSTRACT

OBJECTIVE: We studied the clinical features of children with 3beta-hydroxy-Delta 5-C27-steroid dehydrogenase (3beta-HSDH) deficiency presenting to King's College and Great Ormond Street hospitals between 1989 and 2005. The diagnosis was made biochemically by detection of sulphated dihydroxycholenoic acids and trihydroxycholenoic acids in urine by fast atom bombardment mass spectrometry or electrospray ionisation tandem mass spectrophotometry and a plasma bile acid profile showing absent or low cholic and chenodeoxycholic acid levels and high concentrations of 3beta-7 alpha-dihydroxy-5-cholenoic acid and 3beta-7 alpha-12 alpha-trihydroxy-5-cholenoic acid. RESULTS: Eighteen children (12 male) with 3beta-HSDH deficiency were identified and diagnosed at a median age of 1.35 years (range 8 weeks-11 years). The presenting features included neonatal cholestasis (n = 11), rickets (n = 8, 1 of whom also had hypocalcaemic tetany, seizures, and normal liver biochemical markers), hepatomegaly (n = 7), pruritus (n = 3), and steatorrhoea and failure to thrive (n = 3). Ten children had low serum 25-OH vitamin D levels, of whom 8 also had low vitamin E and 6 had low vitamin A serum levels. Liver histology showed giant cell change and hepatocyte disarray in all with added features of cholestasis in 11, bridging fibrosis in 6, micronodular cirrhosis in 1, fatty change in 1, and active lobular and portal inflammation in 1. Five patients were treated with cholic acid and chenodeoxycholic acid (7 mg x kg(-1) x day(-1) of each), 7 with chenodeoxycholic acid only (7-18 mg x kg(-1) x day(-1)), and 1 with cholic acid (8 mg x kg(-1) x day(-1)) only. Repeated liver biopsies performed in 4 patients 6 months after starting replacement therapy showed improved histological changes. Three children died untreated before 5 years of age. After a median follow-up of 5.5 years (range 1-17 years) 12 out of 13 treated children have no clinical signs of liver disease or of fat-soluble vitamin deficiency. CONCLUSIONS: 3beta-HSDH deficiency is a rare inborn error of metabolism with diverse clinical features. Early replacement treatment leads to clinical and biochemical control and prevents chronic liver and bone disease, at least in the medium term.


Subject(s)
3-Hydroxysteroid Dehydrogenases/deficiency , Bile Acids and Salts/urine , Steroid Metabolism, Inborn Errors/complications , 3-Hydroxysteroid Dehydrogenases/genetics , 3-Hydroxysteroid Dehydrogenases/metabolism , Avitaminosis/etiology , Avitaminosis/genetics , Avitaminosis/metabolism , Chenodeoxycholic Acid/therapeutic use , Child , Child, Preschool , Cholestasis/etiology , Cholic Acid/therapeutic use , Female , Humans , Infant , Liver/pathology , Male , Spectrometry, Mass, Electrospray Ionization , Steatorrhea/etiology , Steroid Metabolism, Inborn Errors/enzymology , Steroid Metabolism, Inborn Errors/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...